Jornal Vascular Brasileiro
https://www.jvascbras.org/article/doi/10.1590/1677-5449.004818
Jornal Vascular Brasileiro
Case Report

Glicose como causa e tratamento de necrose cutânea

Glucose as a cause of and treatment for cutaneous necrosis

Marcelo Luiz Brandão, Amina Muhamad Mota Mustafá, Jordana Lopes Costa

Downloads: 8
Views: 2288

Resumo

A escleroterapia continua sendo um dos procedimentos mais executados pelos cirurgiões vasculares brasileiros. O conhecimento das suas complicações é imprescindível para que possamos evitá-las. Os efeitos colaterais graves desse método de tratamento para as telangiectasias dos membros inferiores são raros e frequentemente associados a um erro técnico ou à dosagem injetada. São predominantemente locais, apresentando-se, algumas vezes, como uma situação de difícil resolução. Relatamos um caso de formação de necrose cutânea após escleroterapia química com glicose hipertônica (75%) e sua cicatrização utilizando preparação tópica contendo vaselina e glicose 60%, cujo resultado estético foi satisfatório.

Palavras-chave

cicatrização; escleroterapia; glicose; telangiectasia; úlcera cutânea; vaselina.

Abstract

Sclerotherapy remains one of the procedures most frequently performed by Brazilian vascular surgeons. Knowledge of its complications is indispensable to enable us to avoid them. The severe side effects of this method of treatment for telangiectasias of the lower limbs are rare and are often associated with technical errors or the dose injected. Complications are predominantly local, but are sometimes difficult to resolve. We report a case of formation of cutaneous necrosis after chemical sclerotherapy using hypertonic glucose (75%), which healed when treated with a topical preparation containing vaseline and 60% glucose, with satisfactory esthetic results.

Keywords

wound healing; sclerotherapy; glucose; telangiectasis; skin ulcer; petrolatum.

References

1. Yiannakopoulou E. Safety concerns for sclerotherapy of telangiectases, reticular and varicose veins. Pharmacology. 2016;98(1-2):62-9. http://dx.doi.org/10.1159/000445436. PMid:27104778.

2. Bertanha M, Sobreira ML, Pinheiro CEP Fo, et al. Polidocanol versus hypertonic glucose for sclerotherapy treatment of reticular veins of the lower limbs: study protocol for a randomized controlled trial. Trials. 2014;15(1):497. http://dx.doi.org/10.1186/1745-6215-15-497. PMid:25527165.

3. Guidelines/Outcomes Committee, Task Force. Guidelines of care for sclerotherapy treatment of varicose and telangiectatic leg veins. J Am Acad Dermatol. 1996;34(3):523-8. http://dx.doi.org/10.1016/S0190-9622(96)90467-3. PMid:8609276.

4. Hobbs JT. Surgery and sclerotherapy in the treatment of varicose veins: a random trial. Arch Surg. 1974;109(6):793-6. http://dx.doi.org/10.1001/archsurg.1974.01360060063016. PMid:4608096.

5. Tisi PV, Beverley C, Rees A. Injection sclerotherapy for varicose veins. Cochrane Database Syst Rev. 2006;4(4):1732. PMid:17054141.

6. Bergan JJ, Weiss RA, Goldman MP. Extensive tissue necrosis following high concentration sclerotherapy for varicose veins. Dermatol Surg. 2000;26(6):535-42, discussion 541-2. http://dx.doi.org/10.1046/j.1524-4725.2000.00033.x. PMid:10848933.

7. Willenberg T, Smith PC, Shepherd A, Davies AH. Visual disturbance following sclerotherapy for varicose veins, reticular veins and telangiectasias: a systematic literature review. Phlebology. 2013;28(3):123-31. http://dx.doi.org/10.1258/phleb.2012.012051. PMid:23761921.

8. Albanese G, Kondo KL. Pharmacology of sclerotherapy. Semin Intervent Radiol. 2010;27(4):391-9. http://dx.doi.org/10.1055/s-0030-1267848. PMid:22550381.

9. Bertanha M, Camargo PA, Moura R, et al. Polidocanol versus glucose in the treatment of telangiectasia of the lower limbs (PG3T): Protocol for a randomized, controlled clinical trial. Medicine. 2016;95(39):4812. http://dx.doi.org/10.1097/MD.0000000000004812. PMid:27684809.

10. Figueiredo M, Figueiredo MF. Pesquisa sobre escleroterapia líquida em varizes dos membros inferiores. Vasc Bras. 2013;12(1):10-5. http://dx.doi.org/10.1590/S1677-54492013000100004.

11. Matsui IA. Estudo do volume injetado de solução de glicose hipertônica a 75% em função do resfriamento. [dissertação]. Campinas: Faculdade de Ciências Médicas, Universidade Estadual de Campinas; 2001.

12. Franceschi C, Bricchi M, Delfrate R. Anti-infective effects of sugarvaseline mixture on leg ulcers. Veins and Lymphatics. 2017;6(2):6652. http://dx.doi.org/10.4081/vl.2017.6652.

13. Merlo I, Brito CJ, Silva RM, et al. Escleroterapia de varizes e substâncias esclerosantes. In: Brito CJ, editor. Cirurgia vascular: cirurgia endovascular, angiologia. Rio de Janeiro: Revinter; 2014. p. 1875-93.

14. Miyake H, Kauffman P, Behmer OA, Wolosker M, Leão LEP. Mecanismo das necroses cutâneas provocadas por injeções esclerosantes no tratamento de microvarizes e telangiectasias: estudo experimental. Rev Ass Med Bras. 1976;22:115-20.

15. Bihari I, Magyar E. Reasons for ulceration after injection treatment of telangiectasia. Dermatol Surg. 2001;27(2):133-6. PMid:11207685.

16. Goldman MP. Sclerotherapy: treatment of varicose and telangiectatic leg veins. 4th ed. St. Louis: Elsevier Ltd; 2006.

17. Miyake RK, King JT, Kikuchi R, Duarte FH, Davidson JRP, Oba C. Role of injection pressure, flow and sclerosant viscosity in causing cutaneous ulceration during sclerotherapy. Phlebology. 2012;27(8):383-9. http://dx.doi.org/10.1258/phleb.2011.011076. PMid:22316599.

18. Munavalli GS, Weiss RA. Complications of sclerotherapy. Semin Cutan Med Surg. 2007;26(1):22-8. http://dx.doi.org/10.1016/j.sder.2006.12.009. PMid:17349559.

19. Franceschi C, Passariello F. Low cost medications for venous ulcer. Sugar-Honey: an on line Vasculab Survey. Acta Phlebol. 2009;10:41-4.

20. Topham J. Sugar for wounds. J Tissue Viab. 2000;10(3):86-9. http://dx.doi.org/10.1016/S0965-206X(00)80035-2. PMid:11299571.

21. Tanner AG, Owen ERTC, Seal DV. Successful treatment of chronically infected wounds with sugar paste. Eur J Clin Microbiol Infect Dis. 1988;7(4):524-5. http://dx.doi.org/10.1007/BF01962604. PMid:3141161.

Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV)"> Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV)">
5cd18b160e88255b25632f90 jvb Articles

J Vasc Bras

Share this page
Page Sections